New treatment options for idiopathic pulmonary fibrosis on the horizon

Background: Idiopathic pulmonary fibrosis (IPF) is a fatal age-related lung disease with limited treatment options. Objective: This article gives an overview of ongoing clinical studies on novel pharmaceuticals for IPF treatment. Material and methods: The publicly available registries of clinical studies were analyzed. Results: Several very promising pharmaceuticals for treatment of IPF are currently in various stages of clinical trials. Conclusion: Due to the large number of ongoing clinical studies and increased interest from the pharmaceutical industry in the development of new forms of treatment, there is hope for the imminent availability of multimodal treatment options for patients with IPF and other forms of lung fibrosis.